|
gptkbp:instanceOf
|
pharmaceutical market
|
|
gptkbp:challenge
|
supply chain issues
Brexit impact
regulatory divergence
pricing pressures
|
|
gptkbp:country
|
gptkb:United_Kingdom
|
|
gptkbp:employs
|
over 70,000 people
|
|
gptkbp:exports_(2022)
|
£25 billion
|
|
gptkbp:focusArea
|
gptkb:biotechnology
clinical trials
generic drugs
innovative medicines
|
|
gptkbp:growth_rate_(2022)
|
3%
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
UK pharmaceutical market
|
|
gptkbp:imports_(2022)
|
£24 billion
|
|
gptkbp:industry
|
pharmaceutical industry
|
|
gptkbp:key_cities
|
gptkb:Cambridge
gptkb:London
gptkb:Manchester
gptkb:Oxford
|
|
gptkbp:market_size_(2022)
|
£50 billion
|
|
gptkbp:NHS_role
|
largest single customer
|
|
gptkbp:notable_imports
|
medical devices
active pharmaceutical ingredients
finished medicines
|
|
gptkbp:notableCompany
|
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Sanofi
gptkb:Novartis
GlaxoSmithKline
|
|
gptkbp:notableExport
|
antibiotics
biologics
oncology drugs
vaccines
|
|
gptkbp:R&D_investment_(2022)
|
£5 billion
|
|
gptkbp:regulates
|
gptkb:Medicines_and_Healthcare_products_Regulatory_Agency
|
|
gptkbp:regulatory_framework
|
EU regulations (pre-Brexit)
UK Medicines Act
UK-specific regulations (post-Brexit)
|
|
gptkbp:trade_association
|
Association of the British Pharmaceutical Industry
|
|
gptkbp:bfsParent
|
gptkb:UK_MHRA
|
|
gptkbp:bfsLayer
|
7
|